Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Growth in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 255,800 shares, a growth of 51.5% from the November 15th total of 168,800 shares. Based on an average trading volume of 616,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 8.7% of the shares of the company are short sold.

Allarity Therapeutics Trading Down 1.9 %

Allarity Therapeutics stock traded down $0.02 during midday trading on Friday, reaching $1.01. The stock had a trading volume of 70,287 shares, compared to its average volume of 253,260. Allarity Therapeutics has a 12 month low of $1.00 and a 12 month high of $378.00. The firm’s 50-day moving average price is $1.36 and its 200 day moving average price is $5.09.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.